Follow Us on Google
By Doris Obinna
Fidson Healthcare Plc, a prominent player in Nigeria’s pharmaceutical sector, has announced a significant expansion initiative aimed at enhancing the country’s healthcare delivery system, alongside a strategic leadership transition.
At its 26th Annual General Meeting (AGM), held virtually on July 31, 2025, in compliance with the Business Facilitation Act, 2022, the company disclosed plans to raise up to ₦30 billion through a rights issue or other equity-based instruments.
The capital injection, according to Fidson, will be directed towards strengthening healthcare infrastructure through the development of new pharmaceutical products, operational upgrades, and regional expansion across Nigeria and other African markets.
This move comes at a crucial time as Nigeria continues to grapple with the need for improved access to quality medicines and sustainable healthcare systems. The company stated that the funds would support innovations to close healthcare gaps and meet the increasing demand for safe, effective medications within the country and beyond.
In a parallel development, Fidson announced the retirement of its founder and Managing Director of three decades, Dr Fidelis Ayebae. He has handed over leadership to Mr Abiola Adebayo, a founding Executive Director with nearly three decades of experience at Fidson.
Adebayo officially assumed the role of Managing Director/Chief Executive Officer on August 1, 2025. His appointment is seen as a move to ensure continuity in the company’s commitment to health innovation and pharmaceutical excellence.
Reflecting on the company’s evolution, Ayebae expressed confidence in the new leadership and the future of healthcare delivery in Nigeria. “As I step down, I do so with immense pride in what we have built together. I now retire knowing that Fidson is in excellent hands with Biola Adebayo, who has been on this journey with me for 29 years. I am confident that his leadership will continue to drive innovation and strategic growth, ensuring the company remains at the forefront of healthcare delivery in Nigeria,” he stated.
Further cementing its role in improving public health, the company declared a dividend payout of ₦1.00 per 50 kobo ordinary share, totalling ₦2.29 billion. This decision underscores Fidson’s financial health and its ongoing investment in strengthening the pharmaceutical landscape in Nigeria.
Additionally, the shareholders approved an increase in share capital from ₦1.2 billion to ₦1.5 billion, reinforcing the company’s capital structure in support of its healthcare-focused expansion strategy.
The AGM also saw the presentation of Fidson’s audited financial statements for the year ended December 31, 2024, as well as the approval of directors’ and auditors’ remuneration. The meeting was marked by notable governance transitions, including the resignation of Board Chairman Mr Segun Adebanji, with a successor expected to be named at the next board session.
With a renewed focus on innovation and regional impact, Fidson’s expansion signals a critical advancement in pharmaceutical manufacturing and healthcare service delivery in Nigeria, reinforcing its mission to provide accessible, high-quality healthcare solutions for all.
